David Ollila
Professor of Surgery
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Year:
2026
Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.
Year:
2025
Background: Recent genome-wide association studies (GWAS) have identified new susceptibility loci for melanoma, but their associations with multiple primary melanoma (MPM) are unclear. Methods: We investigated the associations of 69 SNPs in 39 GWAS-identified loci with odds of MPM relative to single primary melanoma in the international, population-based Genes, Environment, and Melanoma study. Per-minor-allele ORs and 95% confidence intervals (CI) for individuals with MPM “cases” ( n = 1,205) relative to single primary melanoma “controls” ( n = 2,458) were estimated using multivariable logistic regression, and polygenic risk scores (PRS) were calculated and weighted based on a 2020 GWAS meta-analysis (57 of the 68 independent GWAS SNPs available). Results: Thirteen SNPs in 11 gene regions ( PARP1 , CYP1B1/RMDN3 , TERT , RAPGEF5 , TYRP1 , MTAP , CDKN2A/CDKN2B , KLF4 , TYR , SOX6 , and ASIP ) were statistically significantly associated ( P P = 7.5 × 10 −13 ); this association was attenuated but remained statistically significant after excluding SNPs individually associated with MPM (OR = 1.75, 95% CI, 1.32–2.31). Conclusions: Inherited genetic variants spanning 11 gene regions were independently associated with MPM. Nonsignificant SNPs were associated with MPM when aggregated into a PRS, indicating that their cumulative effect may influence MPM risk despite lacking individual statistical significance in our study population. Impact: Our findings provide additional evidence that these loci are associated with melanoma risk and estimate the magnitude of their genetic effect on subsequent (multiple) primary melanoma risk.
Year:
2025
Collaborators (25)
Yuting Lu
New York University
Graham Mann
Professor
University of Sydney
Adam Reynolds
Research Assistant Professor
University of New Mexico
Shaofeng Yan
-
Yongzhao Shao
New York University Grossman School of Medicine
Cheryl Thompson
Professor and Associate Director for Population Sciences, Penn State Cancer Institute
Pennsylvania State University
Christopher I. Amos
Associate Director for Population and Data Science
Baylor College of Medicine
Siok Leong
Memorial Sloan Kettering Cancer Center
Pauline Funchain
Stanford University
Marcus Bosenberg
Professor
Yale University
Marianne Berwick
Professor
University of New Mexico
Marc Ernstoff
Chief
National Institutes of Health
Anne E Cust
Deputy Director, The Daffodil Centre
University of Sydney
Philip M. Spanheimer
Assistant Professor
University of North Carolina
David Polsky
Alfred W. Kopf, M.D. Professor of Dermatologic Oncology and Professor (Clinical) of Pathology (Academic)
NYU School of Medicine
Tim Lee
The University of British Columbia
Pei-Fen Kuan
Professor
Stony Brook University
Paul Googe
Professor and Laboratory Director
University of North Carolina at Chapel Hill
Hoda Anton-Culver
Professor and Chair
University of California, Irvine
James Wilmott
Associate Professor
The University of Sydney Library
Iman Osman
NYU Langone Health
Eva Hernando
Professor
NYU Langone Medical Center
Sheri L. Holmen
Professor
University of Utah Health Sciences Center
Richard A. Scolyer
Faculty Member
University of Sydney
E. Nagore
Profesor Asociado
Universidad Católica de Valencia San Vicente Mártir Facultad de Medicina Facultad de Medicina y Odontología
Make your next move.
Prepare your application
Review drafts before you send them.